Canada markets closed

Checkpoint Therapeutics, Inc. (CZTA.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
2.0000+0.1600 (+8.70%)
At close: 06:41PM CEST
Full screen
Previous Close1.8400
Open1.8840
Bid1.9120 x N/A
Ask1.9620 x N/A
Day's Range1.8840 - 2.0000
52 Week Range1.2860 - 3.0380
Volume2,000
Avg. Volume161
Market Cap72.752M
Beta (5Y Monthly)1.13
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Checkpoint Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference

    WALTHAM, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James Oliviero, President and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ, taking place on Monday, May 20, 2024, at 12:30 p.m. ET. Checkpoint will also attend in-person one-on-one meetings during the conference. A w

  • GlobeNewswire

    Checkpoint Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Updates

    WALTHAM, Mass., May 10, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial results for the first quarter ended March 31, 2024, and recent corporate updates. James F. Oliviero, President and Chief Executive Officer of Checkpoint, said, “Over the past few months, we have worked closely with our third-party contract manufacturing organization (“CMO”) for cosibelimab to resolve

  • GlobeNewswire

    Checkpoint Therapeutics Reports Full-Year 2023 Financial Results and Recent Corporate Highlights

    WALTHAM, Mass., March 22, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial results for the full-year ended December 31, 2023, and recent corporate highlights. James F. Oliviero, President and Chief Executive Officer of Checkpoint, said, “We continue to work closely with our third-party contract manufacturing organization to expeditiously resolve the deficiencies noted in t